Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Myriad Genetics and CancerCARE for Life announced an agreement designed to enhance education and access to hereditary cancer testing.
-
Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay.
-
Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.
-
Myriad Genetics will unveil groundbreaking eight weeks’ gestation NIPT study results at the annual SMFM conference.
-
Myriad Genetics launches a new educational website providing information about reproductive and prenatal genetic testing called "Know More Sooner."
-
Myriad Genetics announced a hereditary cancer risk assessment program study was published in Obstetrics & Gynecology (also known as The Green Journal).
-
Myriad Genetics announces select preliminary fourth quarter and full year 2024 financial results and introduces full year 2025 financial guidance.
-
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history.
-
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
-
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.